Ocuphire Announces Upcoming Presentations at European Forum 2022, [email protected] 2022 and the American Academy of Ophthalmology 2022 Annual Meeting Sep 15, 2022
Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy Sep 8, 2022
Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference Sep 6, 2022
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update Aug 12, 2022
Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance Aug 3, 2022
Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July Jul 7, 2022
Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication Jun 29, 2022
Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting Jun 8, 2022
